{"disease":{"id":"influenza-prevention","name":"Influenza prevention","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":3,"pipeline_drug_count":0,"trial_count":1},"drugs":{"marketed":[{"drug_id":"licensed-influenza-vaccine","indication_name":"Influenza prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Assorted Licensed Hand Sanitizer Grape 01","generic_name":"Licensed influenza vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"vaccine","quality_score":55,"revenue":null,"mechanism":"The mechanism of action is not specified."},{"drug_id":"amantadine","indication_name":"Influenza A Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gocovri","generic_name":"AMANTADINE","company_name":"Endo","drug_phase":"marketed","molecular_target":"Sigma non-opioid intracellular receptor 1","drug_class":"Influenza A M2 Protein Inhibitor","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"licensed-influenza-vaccine-2","indication_name":"Influenza prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Licensed Influenza Vaccine 2","company_name":"BioNTech","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Vaccine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"licensed-influenza-vaccine-2","indication_name":"Influenza prevention for adults and children 6 years and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Licensed Influenza Vaccine 2","company_name":"BioNTech","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Vaccine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"qiv","indication_name":"Influenza prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Qiv","generic_name":"qiv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Influenza viruses","drug_class":"Inactivated vaccine","quality_score":37,"revenue":null,"mechanism":""},{"drug_id":"gocovri","indication_name":"Influenza A Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"GOCOVRI","company_name":"Oregon Health and Science University","drug_phase":"marketed","molecular_target":"Sigma non-opioid intracellular receptor 1","drug_class":"Influenza A M2 Protein Inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"amantadin","indication_name":"Influenza A Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Amantadin","company_name":"Centre Hospitalier Universitaire de Nice","drug_phase":"marketed","molecular_target":"Multidrug and toxin extrusion protein 1, Sigma non-opioid intracellular receptor 1, Glutamate [NMDA] receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":7,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06280144","title":"Post-marketing Study of Lyophilized Nasal Spray Live Attenuated Influenza Vaccine","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":6080,"lead_sponsor_name":"Changchun BCHT Biotechnology Co.","has_results":false},{"nct_id":"NCT06800950","title":"Phase III Clinical Trial of Quadrivalent Influenza Virus Split Vaccine","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":4400,"lead_sponsor_name":"Institute of Medical Biology, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT05284851","title":"The Safety and Immunogenicity Evaluation of Live Attenuated Influenza Vaccine","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":2520,"lead_sponsor_name":"Changchun BCHT Biotechnology Co.","has_results":false},{"nct_id":"NCT05071313","title":"A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":777,"lead_sponsor_name":"Janssen Vaccines & Prevention B.V.","has_results":true},{"nct_id":"NCT05901636","title":"A Clinical Study to Evaluate an Experimental Universal Influenza Vaccine, INFLUENZA G1 mHA, in Healthy Adults","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":170,"lead_sponsor_name":"Janssen Vaccines & Prevention B.V.","has_results":true},{"nct_id":"NCT05056519","title":"The Safety and Immunogenicity Evaluation of Live Attenuated Influenza Vaccine","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":160,"lead_sponsor_name":"Changchun BCHT Biotechnology Co.","has_results":false},{"nct_id":"NCT07111078","title":"Quadrivalent Influenza HA Stem Vaccine VRC-FLUMOS0122-00-VP (SteMos1) With and Without ALFQ Adjuvant in Healthy Adults","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":56,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT03370289","title":"A Phase 4 Post-marketing Study of Intramuscular Injections of BLB-750 in Healthy Adult Subjects","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":55,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT04297462","title":"Different Regimens in Influenza Postexposure Chemoprophylaxis in Children","phase":"NA","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Centre of Postgraduate Medical Education","has_results":false},{"nct_id":"NCT06863142","title":"Evaluating the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRCFLUMOS0116-00-VP (FluMos-v2) With and Without ALFQ Adjuvant in Healthy Adults","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false}],"total":10},"guidelines":[],"source":"Drug Landscape verified database"}